GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Additional Paid-In Capital

Alto Neuroscience (Alto Neuroscience) Additional Paid-In Capital : $283.57 Mil(As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Additional Paid-In Capital?


Alto Neuroscience's quarterly additional paid-in capital increased from Sep. 2023 ($4.74 Mil) to Dec. 2023 ($5.37 Mil) and increased from Dec. 2023 ($5.37 Mil) to Mar. 2024 ($283.57 Mil).

Alto Neuroscience's annual additional paid-in capital increased from Dec. 2021 ($0.49 Mil) to Dec. 2022 ($2.30 Mil) and increased from Dec. 2022 ($2.30 Mil) to Dec. 2023 ($5.37 Mil).

Alto Neuroscience Additional Paid-In Capital Historical Data

The historical data trend for Alto Neuroscience's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Additional Paid-In Capital Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
0.49 2.30 5.37

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 2.30 - 4.74 5.37 283.57

Alto Neuroscience Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Alto Neuroscience Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024